Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- Sikov, William M.
- Berry, Donald A.
- Perou, Charles M.
- Singh, Baljit
- Cirrincione, Constance T.
- Tolaney, Sara M.
- Kuzma, Charles S.
- Pluard, Timothy J.
- Somlo, George
- Port, Elisa R.
- Golshan, Mehra
- Bellon, Jennifer R.
- Collyar, Deborah
- Hahn, Olwen M.
- Carey, Lisa A.
- Hudis, Clifford A.
- Winer, Eric P.
Publication date
January 2015
DOIAbstract
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × 2 factorial, open-label, randomized phase II trial, evaluated the impact of adding carboplatin and/or bevacizumab
Add to ORKG